drugset / Trial / NCT00401544

Darbepoetin Alfa With or Without Intravenous (IV) Iron

NCT00401544

Phase 2 Completed 243 enrolled Amgen
RandomizedFactorialQuadruple-blindTreatment

Summary

To deterime the efficacy of 500 μg and 300 μg darbepoetin alfa administered subcutaneously (SC) on an every 3 weeks (Q3W) schedule, and the effect of intravenous (IV) iron supplementation in the treatment of anemia in patients with non-myeloid malignancies who were receiving multicycle chemotherapy.

Timeline

Start
2006-12
Primary completion
2007-12
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Darbepoetin alfa Protein / enzyme biologic 300 ug Subcutaneous
Subject Darbepoetin alfa Protein / enzyme biologic 500 ug Subcutaneous
Subject Iron dextran Unknown 400 mg Intravenous

Indications